John Brancaccio Biography and Net Worth

Director of Cardiff Oncology

John Brancaccio, a retired CPA, has been a Director since December 2005. Mr. Brancaccio currently serves on the boards of Rasna Therapeutics, Inc. since 2016, Hepion Pharmaceuticals, Inc. since 2013, and Tamir Biotechnology, Inc. (formerly Alfacell Corporation) since 2004. Previously, Mr. Brancaccio served as Chief Financial Officer of Accelerated Technologies, Inc., an incubator for medical device companies from 2004 until his retirement in 2017. The Board believes Mr. Brancaccio’s experience as a chief financial officer provides valuable financial and accounting expertise that qualifies him to serve as a director of our company.

What is John P. Brancaccio's net worth?: The estimated net worth of John P. Brancaccio is at least $71,014.20 as of September 15th, 2023. Mr. Brancaccio owns 16,670 shares of Cardiff Oncology stock worth more than $71,014 as of December 22nd. This net worth estimate does not reflect any other assets that Mr. Brancaccio may own. Learn More about John P. Brancaccio's net worth.
How do I contact John P. Brancaccio?: The corporate mailing address for Mr. Brancaccio and other Cardiff Oncology executives is 11055 FLINTKOTE AVENUE, SAN DIEGO CA, 92121. Cardiff Oncology can also be reached via phone at (858) 952-7570 and via email at [email protected]. Learn More on John P. Brancaccio's contact information.
Has John P. Brancaccio been buying or selling shares of Cardiff Oncology?: John P. Brancaccio has not been actively trading shares of Cardiff Oncology over the course of the past ninety days. Most recently, on Monday, March 22nd, John P. Brancaccio bought 3,000 shares of Cardiff Oncology stock. The stock was acquired at an average cost of $10.95 per share, with a total value of $32,850.00. Following the completion of the transaction, the director now directly owns 12,260 shares of the company's stock, valued at $134,247. Learn More on John P. Brancaccio's trading history.
Who are Cardiff Oncology's active insiders?: Cardiff Oncology's insider roster includes John Brancaccio (Director), Mark Erlander (CEO), Vicki Kelemen (COO), James Levine (CFO), Rodney Markin (Director), and Gary Pace (Director). Learn More on Cardiff Oncology's active insiders.
Are insiders buying or selling shares of Cardiff Oncology?: In the last year, Cardiff Oncology insiders bought shares 1 times. They purchased a total of 350,115 shares worth more than $910,299.00. The most recent insider tranaction occured on December, 11th when Director Gary W Pace bought 350,115 shares worth more than $910,299.00. Insiders at Cardiff Oncology own 7.8% of the company. Learn More about insider trades at Cardiff Oncology.
Information on this page was last updated on 12/11/2024.

John P. Brancaccio Insider Trading History at Cardiff Oncology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/22/2021	Buy	3,000	$10.95	$32,850.00	12,260

John P. Brancaccio Buying and Selling Activity at Cardiff Oncology

Cardiff Oncology Company Overview

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Today's Range

Now: $4.26

$4.20

$4.67

50 Day Range

MA: $3.08

$2.31

$5.35

2 Week Range

Now: $4.26

$1.41

$6.42

Volume

2,098,097 shs

Average Volume

1,215,761 shs

Market Capitalization

$217.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.89

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...

I put all the details together for you here — but please hurry.